These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28521029)

  • 41. Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors.
    Jacob CO; Yu N; Sindhava V; Cancro MP; Pawar RD; Putterman C; Stohl W
    Arthritis Rheumatol; 2015 Sep; 67(9):2523-35. PubMed ID: 25989238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.
    Visram A; Soof C; Rajkumar SV; Kumar SK; Bujarski S; Spektor TM; Kyle RA; Berenson JR; Dispenzieri A
    Blood Cancer J; 2021 Jun; 11(6):120. PubMed ID: 34168119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.
    Baraniskin A; Zaslavska E; Nöpel-Dünnebacke S; Ahle G; Seidel S; Schlegel U; Schmiegel W; Hahn S; Schroers R
    Neuro Oncol; 2016 Mar; 18(3):361-7. PubMed ID: 26250566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
    Chiu A; Xu W; He B; Dillon SR; Gross JA; Sievers E; Qiao X; Santini P; Hyjek E; Lee JW; Cesarman E; Chadburn A; Knowles DM; Cerutti A
    Blood; 2007 Jan; 109(2):729-39. PubMed ID: 16960154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Correlation Between Non-Hodgkin Lymphoma and Expression Levels of B-Cell Activating Factor and Its Receptors.
    Shen X; Wang M; Guo Y; Ju S
    Adv Clin Exp Med; 2016; 25(5):837-844. PubMed ID: 28028945
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of B-cell activating factor, a proliferating inducing ligand and its receptors in primary central nervous system lymphoma.
    Birnbaum T; Langer S; Roeber S; von Baumgarten L; Straube A
    Neurol Int; 2013 Feb; 5(1):e4. PubMed ID: 23717783
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma.
    Watanabe J; Natsumeda M; Kanemaru Y; Okada M; Oishi M; Kakita A; Fujii Y
    Leuk Lymphoma; 2019 Dec; 60(14):3587-3589. PubMed ID: 31305194
    [No Abstract]   [Full Text] [Related]  

  • 49. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma.
    Baraniskin A; Kuhnhenn J; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2012 Sep; 109(2):239-44. PubMed ID: 22729947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity.
    Yu G; Boone T; Delaney J; Hawkins N; Kelley M; Ramakrishnan M; McCabe S; Qiu WR; Kornuc M; Xia XZ; Guo J; Stolina M; Boyle WJ; Sarosi I; Hsu H; Senaldi G; Theill LE
    Nat Immunol; 2000 Sep; 1(3):252-6. PubMed ID: 10973284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma.
    Murase S; Saio M; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Takami T
    Cancer Lett; 1998 Oct; 132(1-2):181-6. PubMed ID: 10397472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus.
    Tran NL; Schneider P; Santiago-Raber ML
    Eur J Immunol; 2017 Apr; 47(4):713-723. PubMed ID: 28267197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma.
    Miao YR; Thakkar K; Cenik C; Jiang D; Mizuno K; Jia C; Li CG; Zhao H; Diep A; Xu Y; Zhang XE; Yang TTC; Liedtke M; Abidi P; Leung WS; Koong AC; Giaccia AJ
    J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35881112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of primary central nervous system lymphoma.
    Ekenel M; DeAngelis LM
    Curr Neurol Neurosci Rep; 2007 May; 7(3):191-9. PubMed ID: 17488584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroinflammation preceding primary central nervous system lymphoma (PCNSL) - Case reports and literature review.
    Norrington M; Rathi N; Jenkinson MD; Mills SJ
    J Clin Neurosci; 2021 Jul; 89():381-388. PubMed ID: 34083111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inflammatory Markers and Immune Response to Pneumococcal Vaccination in HIV-Positive and -Negative Adults.
    Iyer AS; Khaskhely NM; Leggat DJ; Ohtola JA; Saul-McBeth JL; Khuder SA; Westerink MA
    PLoS One; 2016; 11(3):e0150261. PubMed ID: 26930208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
    Sasagawa Y; Akai T; Tachibana O; Iizuka H
    J Neurooncol; 2015 Jan; 121(1):177-83. PubMed ID: 25258254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement.
    Lin Z; Yu N; Cheng C; Jin B; Zhang Q; Zhuang H; Jiang X
    Lupus; 2023 Apr; 32(5):680-687. PubMed ID: 36914971
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma.
    Whitcup SM; Stark-Vancs V; Wittes RE; Solomon D; Podgor MJ; Nussenblatt RB; Chan CC
    Arch Ophthalmol; 1997 Sep; 115(9):1157-60. PubMed ID: 9298057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.
    Ungureanu A; Le Garff-Tavernier M; Costopoulos M; Parratte T; Brinet A; Durand H; Gaultier C; Hurstel R; Alamome I; Sellal F; Ahle G
    J Neurol; 2021 Aug; 268(8):2890-2894. PubMed ID: 33609156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.